CSL Limited

Marcus Today’s Henry Jennings is unimpressed by CSL’s results - and even less so by its handling of the CEO change.

After years of flawless growth, CSL’s streak has broken. So, what's next for this fallen titan of the Australian corporate landscape?

After announcing soft guidance, a spin off of its vaccines unit, and plans to cut 3000 jobs, investors are pondering CSL's future.

One fund manager warns CBA investors may face the five years of dismal returns that CSL investors have worn.

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

Australia's biggest healthcare stock disappointed on guidance for FY25, sending its share price south.

CSL has delivered bumper returns once again in its half-year report but suffered a major setback this week.

CSL has form in creating a sustainable competitive advantage by combining product portfolios, manufacturing and distribution to drive significant shareholder value....

Picture 8,000 Boeing 747s crammed with glass vials and syringes – no, it isn’t a novel solution to airlines’ COVID woes, but a stark illustration of the logistical...

Last month, I was sitting in a hotel lobby (actually the Bar) in Amsterdam after attending the International Plasma Protein Conference. I started talking with a fellow...